Interferon-α alone versus interferon-α plus ribavirin in patients with chronic hepatitis C not responding to previous interferon-α treatment

BioDrugs

Volumn 13, Issue 4, 2000, Pages 299-304

  Tripi, S ^a   Di Gaetano, G ^a   Soresi, M ^a   Cartabellotta, F ^b   Vassallo, R ^b   Carroccio, A ^a   Anastasi, G ^a   Montalto, G ^a,c  

^a UNIVERSITY OF PALERMO   (Italy)

^b Buccheri La Ferla Hospital   (Italy)

^c Cattedra di Medicina Interna   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ANEMIA; ARTICLE; CLINICAL TRIAL; DEPRESSION; FEMALE; HEPATITIS C; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; RNA ANALYSIS; SEROLOGY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0034013926     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200013040-00008     Document Type: Article

References (28)

1. 1. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-56
2. 2. Poynard T, Leroy V, Cohard M. et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-89
3. 3. Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology 1992; 15: 1013-6
4. 4. Mondazzi L, Bottelli R, Zavaglia C, et al. Chronic hepatitis C: long-term follow-up of sustained responders to alpha-1FN treatment [abstract]. Hepatology 1993; 18: 91A
5. 5. Hopf U, Kuther S, Konig V. Langzeitbeobachtung der chronischen C nach Behandlungmit rekombinantem Interferon alpha-2a. Z Gastroenterol 1994; 32: 425-30
6. 6. Montalto G, Tripi S, Cartahellotta A, et al. Intravenous natural beta-interferon in white patients with chronic hepatitis C who are non-responders to alfa-interferon. Am J Gastroenterol 1998; 93: 950-3
7. 7. Kakumu S, Yoshioka K, Wakita T et al. A pilot study of ribavirin and Interferon beta for the treatment of chronic hepatitis C. Gastroenterology 1993; 105: 5078-82
8. 8. Tripi S, Di Gaetano G, Soresi M, et al. Acetylcysteine therapy for chronic hepatitis C. Are its effects synergistic with Interferon alpha? Clin Drug Invest 1998; 16: 297-302
9. 9. Boucher E, Jouanolle H, Andre P, et al. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients. Hepatology 1995; 21: 322-7
10. 10. Chayma K, Tsubota A, Kobayachi M, et al. A pilot study of corticosteroid priming for lymphoblastoid interferon in patients with chronic hepatitis C. Hepatology 1996; 23: 953-7
11. 11. Brillanti S, Miglioli M, Barbara L. Combination antiviral therapy with ribavirin and interferon alpha in interferon alfa relapsers and non-responders: Italian experience. J Hepatol 1995; 23 Suppl.: 13-6
12. 12. Schvarcz R, Ando YY, Soneerborg A, et al. Combination treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to Interferon alone: Swedish experience. J Hepatol 1995; 23 Suppl: 17-21
13. 13. Moreno-Monteagudo JA, Fernandez-Bermejo M, Garcia-Buey L, et al. Interferon alpha with ribavirin for the treatment of chronic hepatitis C in non-responders or relapsers to interferon monotherapy. Aliment Pharmacol Ther 1998; 12: 717-23
14. 14. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alpha 2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493-6
15. 15. Chemello L, Cavalletto L, Bernardinello E, et al. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995; 23 Suppl.: 8-12
16. 16. Lai MY, Kao JH, Yang PM, et al. Long-term efficacy of ribavirin plus interferon alpha in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 1307-12
17. 17. Reichard O, Norkrans G, Fryden A, et al. Randomised, doubleblind, placebo-controlled trial of interferon alpha 2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-7
18. 18. Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25: 591-8
19. 19. Bodenheimer Jr HC, Lindsay KL, Davis GL, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26: 472-83
20. 20. Giannini C, Thiers V, Nousbaum JB, et al. Comparative analysis of two assays for genotyping hepatitis C virus (HCV) based on genotype-specific primers of probes. J Hepatol 1995; 23: 246-53
21. 21. Kwok S, Higuchi R. Avoiding false positive results with PCR. Nature 1989; 339: 237-8
22. 22. Montalto G, Soresi M, Carroccio A, et al. Comparative response of three different types of interferon alpha in patients with chronic hepatitis C. Curr Med Res Opin 1998; 14: 235-41
23. 23. Pistello M, Maggi F, Vatteroni L, et al. Prevalence of hepatitis C virus genotypes in Italy. J Clin Microbiol 1994; 32: 232-4
24. 24. Pontisso P, Ruvoletto MG, Nicoletti M, et al. Distribution of three major of hepatitis C virus genotypes in Italy: a multicenter study of 495 patients with chronic hepatitis C. J Viral Hepat 1995; 2: 33-8
25. 25. Pozzato G, Moretti M, Franzin F, et al. Severity of liver disease with different HCV clones. Lancet 1991; 338: 509
26. 26. Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum HCV-RNA levels and HCV genotype are the main independent prognostic factors of sustained response to alpha-interferon therapy in chronic hepatitis C. Hepatology 1995; 22: 1050-6
27. 27. Montalto G, Zignego AL, Ruggeri MI, et al. Serum HCV-RNA and liver histologic findings in patients with long-term normal transaminases. Dig Dis Sci 1997; 42: 1703-7
28. 28. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading, staging. Hepatology 1994; 19: 1513-20